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Abbreviations 
EC(s) = Endothelial(s) cells 
TNF-α = Tumor Necrosis Factor 
Act D = Actinomycin D 
MTT = (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
 r.Ad. = recombinant adenovirus 
BAEC = bovine aortic ECs  
HMEC = human dermal microvascular endothelial cells  
HUVEC  = human umbilical vein endothelial cells 
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Abstract 
 
Anti-apoptotic genes including those of the Bcl-2 family have been shown to 
have dual functionality in as much as they inhibit cell death but also regulate 
inflammation. Several anti-apoptotic molecules have been associated with 
endothelial cell (EC) survival following transplantation however their exact role 
has yet to be elucidated in respect to controlling inflammation. In this study we 
created mice expressing murine A1 (Bfl-1), a Bcl-2 family member, under the 
control of the human ICAM-2 promoter. Constitutive expression of A1 in murine 
vascular ECs conferred protection from cell death induced by the pro-
inflammatory cytokine TNF-α. Importantly, in a mouse model of heart allograft 
transplantation, expression of A1 in vascular endothelium increased survival in 
the absence of CD8+ T cells. Better graft outcome in mice receiving an A1 
transgenic heart correlated with a reduced immune infiltration, which maybe 
related to increased EC survival and reduced expression of adhesion molecules 
on ECs. In conclusion, constitutive expression of the anti-apoptotic molecule 
Bfl1 (A1) in murine vascular ECs leads to prolonged allograft survival due to 
modifying inflammation.  
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Introduction 
Endothelial cells (ECs) lining blood vessels function at the interface between 
the blood stream and tissue. EC activation and death is believed to be key 
initiating events in the development of transplant vascular disease [1]. This idea 
is supported by the strong correlation between graft survival and expression of 
protective genes in vascular ECs. In animal models, where long-term allograft 
survival was established, expression of anti-apoptotic molecules A20, heme 
oxygenase-1 (HO-1), Bcl-xL and Bcl-2 were observed in graft ECs [2-5]. Some 
of these molecules have a dual cytoprotective role, in as much as, they inhibit 
cell death but are also act as anti-inflammatory mediators. For example, A20 
has been shown to inhibit NF-kB activation to a number of stimuli, including 
oxidative stress and inflammatory cytokines [6,7]. Recently, over expression of 
A20 in the vasculature, both ECs and smooth muscle cells (SMCs), using 
recombinant A20 adenovirus, reduced transplant arteriosclerosis in a mouse 
aorta, to carotid artery, allograft model [8]. Protection correlated with decreased 
graft inflammation, with the infiltrating cells being predominantly regulatory T 
cells (Tregs), suggesting that maintaining the endothelium in a damage free 
state may help tip the balance towards transplant tolerance [8]. 
 
A1, known as Bfl-1 in the human setting [9], is another anti-apoptotic molecule 
with dual cytoprotective abilities [9-14]. Unlike Bcl-2 and Bcl-xL, the expression 
of A1 is rapidly induced in ECs following stimuli from pro-inflammatory cytokines 
such as tumor necrosis factor (TNF-α) and IL-1β [15]. NF-kB activation is 
required for the induction of A1 in ECs [10,16]. Expression of A1, following 
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retrovirus transduction, protected both human dermal microvascular endothelial 
cells (HMEC-1) and human umbilical vein endothelial cells (HUVEC) against 
TNF-α induced apoptosis [15,17,18]. Induced expression of A1 not only 
inhibited ECs death but also their activation (reduction of E-selectin levels and 
IL-8 production) making this molecule a potential regulator of inflammation [10]. 
A1 may regulate inflammation in ECs by inhibiting NF-kB activation given that 
expression of full length A1 in bovine aortic ECs (BAEC) inhibited TNF-α-
mediated IKBα degradation and subsequently NF-kB activation [10,16].  
 
Due to the anti-apoptotic and anti-inflammatory nature of A1, we investigated 
the role of this molecule in graft outcome when constitutively expressed in the 
vascular endothelium. To achieve this, we generated mice expressing the 
mouse A1 gene under the control of the human ICAM-2 promoter [19] and 
assessed the role of this molecule in a vascular transplant setting. We observed 
that expression of A1 in ECs conferred protection in a murine heart transplant 
setting due to maintaining ECs in a non-inflammatory state [20,21]. 
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Materials and Methods 
 
Animal studies were carried out in accordance with UK Research Councils and 
Medical Research Charities guidelines on responsibility in the use of animals in 
Bioscience Research, under a UK Home Office Licence (PPL70/7302). 
Anesthesia used was Isoflurane Euthanasia was via CO2 inhalation. 
 
ICAM-2/A1 transgenic mice 
The human ICAM-2 containing pBluescript II SK+ plasmid was kindly provided 
by Dr Peter Cowan (St Vincent's Hospital, Australia) and the murine A1-a cDNA 
containing pBluesK plasmid was kindly provided by Prof. Michael B Prystowskyt 
(Albert Einstein College of Medicine, USA). Murine A1 was excised from the 
plasmid using HindIII and BamH1 restriction digestion before being ligated into 
the ECOR1 cloning site of pBluescript II SK+ plasmid, upstream of the ICAM-2 
promoter and the universal intron. A 1.6kb microinjection construct containing 
both the ICAM-2 promoter and A1 gene was excised from the vector by Xho1 
and Not1 enzyme restriction digestion. The injection fragment (1.6Kb) was then 
separated by agarose gel electrophoresis, followed by purification through 
sequential Wizard mini columns (Promega, Madison, WI) and CHROMA SPIN 
400 (CLONTECH, Palo Alto, CA). The purified fragment was microinjected at a 
concentration of 10µg/ml in phosphate-buffered saline into fertilized 
CBA×C57BL6 mouse oocytes (Karolinska Institute, Sweden). Founder progeny 
were screened for transgene integrity by Southern Blot analysis using the 32P-
labeled 1600bp injection fragment as a probe. In addition, mice were screened 
using PCR using ICAM-A1 forward primer (5’-TTTGCAGAAGGCTAGGGAT-3’) 
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and the reverse primer (5’- TTCAACTTCCTTCTGAACGG-3’). The resulting 356 
base pair product was resolved by electrophoresis in 1% agarose. Transgenic 
founders were breed onto a C57BL/6 (B6) background for more than ten 
generations. Mice were kept under sterile conditions.  
 
EC isolation and cell culture 
Murine ECs were purified from murine heart tissue using a method previously 
described [22]. In brief, murine hearts were digested with collagenase (from 
clostrium hostolyticum Type IV, Sigma Aldrich) and trypsin (Invitrogen Paisley, 
UK) to obtain a single cell suspension. ECs were isolated following incubation 
with rat anti-CD31, anti-CD105 (BD Biosciences) and biotinylated Isolectin B4 
(Vector Laboratories, Peterborough, UK) specific antibodies and anti-rat Ig and 
streptavidin coupled bead selection, using MS columns (Miltenyi Biotech, 
Germany). ECs were then cultured for 7-10 days in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 20% FCS (GE Healthcare), 2mM 
glutamine and Penicillin/Streptomycin, 50mM 2-Mercaptoethanol, 1% Non-
essential amino acids, 1mM Sodium Pyruvate, 20mM Hepes (Invitrogen, 
Paisley, UK) and EC growth factors (Sigma Aldrich) at 37oC/5% CO2. Once the 
cells had reached 90% confluence they were harvested using trypsin and re-
plated. For functional assays, ECs were used between passage 3 and 4. ECs at 
a 90% confluence were used for all experiments. To check that the cultured 
cells were indeed ECs, cells were harvested using Accutase (Invitrogen) and 
stained with anti-CD105-PE labeled antibodies before being analysed by flow 
cytometry (BD Calibur). Subsequent analysis was accomplished with FlowJo 
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software (TreeStar, USA). To test A1 mRNA expression in the cultured ECs, 
cells were lysed using Trizol and RNA extracted using an RNeasy mini kit 
(Qiagen, USA). A one step RT-PCR kit (Promega) was used with the following 
primers 5’-AACTTCCACAAGAGCAGATTGCC-3’ and 5’-
TCAGCCAGCCAGATTTGGGTTC-3’ to amplify A1 mRNA. 
 
MTT cell survival assay  
2.5x104 ECs were added to each well of a 96-well plate in complete media 
lacking Phenol red (Invitrogen). Various concentrations of TNF-α (First Link UK 
Ltd, Brierley Hill, UK) were added with or without 1µg/ml of Actinomycin D (Act 
D, Sigma Aldrich). Control cells were incubated with Act D alone. A MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was 
performed after 18 hours following manufactures instructions (Invitrogen). 
 
Heart Transplantation 
Intra-abdominal heterotopic heart transplantation (either ICAM-2/A1 or non-
transgenic grafts) was performed in CBA mice (Harlan), as previously described 
[23]. Heart allograft survival was assessed by direct abdominal palpation, where 
rejection was defined by complete cessation of cardiac impulses. Some mice 
were treated with 250μgs of anti-CD8 antibody, one day prior to and after 
transplantation, via intraperitoneal injection. Hearts were isolated on day 100, 
sectioned and stained with H&E. 
 
Measuring expression of adhesion molecules 
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2.5x104 ECs were grown to 90% confluent in 6 well plates at 37oC/5% CO2. 
10ngs/ml of TNF-α was added for 24 hours. Cells were removed from the plate 
using Accutase before being incubated with Fc block (anti-CD16/32 antibody, 
eBioscience, UK) for 30 minutes at 4oC. Cells were then stained with anti-ICAM-
1 or anti-VCAM-1 FITC antibodies or isotype controls (eBioscience) before 
being analysed by flow cytometry and FlowJo software. 
 
Statistics 
Statistical comparisons for experiments assessing in vitro proliferation were 
performed using unpaired two-tailed Student t tests [24]. Mean survival time of 
heart allografts was assessed by Logrank test. Statistical significance is 
expressed as (*) and is defined as p values lower than 0.05. 
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Results 
Constitutive expression of A1 in ECs prolongs the survival of transplanted 
hearts 
 
As both anti-apoptotic molecules Bcl-2 and Bcl-xL have been implicated in 
protecting graft ECs during transplantation, we addressed whether the 
expression of A1 in ECs also has this capacity. To this end we generated mice 
expressing murine A1 in ECs (ICAM-2/A1 mice, Figure 1 A and B). We used the 
human ICAM-2 promoter to target A1 to ECs. This promoter has previously 
been shown to target human CD59 expression to the endothelium of all tissues 
[25,26] due to the high expression of ICAM-2 on all vascular ECs, including 
those of the heart [27]. Indeed ECs, identified by their expression of CD105 [22] 
(Figure 1C, top panels), isolated and expanded from the hearts of ICAM-2/A1 
mice expressed A1 at the mRNA level (Figure 1C, lower panels). In 
comparison, ECs isolated from non-transgenic mice did not. Therefore 
confirming the expression of the A1 gene in ECs isolated from these transgenic 
mice.  
 
To assess whether constitutive A1 protected the endothelium in vivo from 
immune mediated damage elicited during transplantation, we transplanted 
hearts derived from ICAM-2/A1 mice (on a B6 background) or non-transgenic 
littermates into CBA/Ca recipients. We observed rapid rejection of donor hearts 
in recipient mice regardless of the expression of the A1 gene (mean survival 
time was day 6 and 7.5 for non-transgenic and ICAM-2/A1 transgenic donor 
hearts, respectively, p=0.08, Figure 2A). We have previously shown that 
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treatment of recipient mice with anti-CD8 antibody, to remove the contribution of 
CD8+ T cells to graft rejection, allowed prolongation of heart transplants in a 
complete mismatched transplant model [23]. In conjunction with anti-CD8 
therapy treatment, given one day prior to and after heart transplantation, 
constitutive expression of A1 on ECs lead to significant heart transplant survival 
as compared to control hearts (mean survival time was 86 days versus 17 for 
ICAM-2/A1 hearts versus non-transgenic littermates, p<0.001 and Figure 2B). 
Overall these observations suggest that expression of this anti-apoptotic gene 
did not protect ECs against direct CD8 mediated killing however when anti-CD8 
antibody was used A1 expression by the graft significantly improved transplant 
outcome. 
 
Murine vascular ECs expressing A1 are less susceptible to cytokine- 
mediated activation 
 
Given the transplant survival data it was important to understand how 
constitutive expression of A1 contributes towards graft protection. The pro-
inflammatory cytokine TNF-α has been shown to be an important mediator of 
allograft rejection [28] with prolongation of allograft hearts survival being 
reported in recipient mice lacking the TNF receptor [29]. As over expression of 
A1, using retrovirus transduction, protected human ECs against TNF-α induced 
apoptosis [15] we tested whether constitutive expression of A1 protected 
murine ECs from TNF-α induced cell death. ECs isolated from the hearts of 
ICAM-2/A1 transgenic mice were treated with different concentrations of TNF-α 
(0.01 to 100ngs/ml) in the presence of Act D (1µg/ml) for 24 hours. Cell viability 
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was measured using an MTT assay. No significant EC death was evident in the 
presence of Act D (data not shown) and ECs treated with Act D only were 
deemed to be 100% viable. We observed that after 24 hours of treatment with 
either 0.01 or 0.1ng/ml of TNF-α in combination with Act D, ECs isolated from 
ICAM-2/A1 transgenic mice were less susceptible to cytokine induced cell death 
than ECs from non-transgenic mice (p values were 0.003 and 0.023, 
respectively). However treatment with higher doses, 1, 10 and 100ngs/ml TNF-
α plus Act D, induced similar levels of cell death in ECs isolated from either 
ICAM-2/A1 transgenic or non-transgenic mice (Figure 3A). Suggesting that 
constitutive A1 expression in heart ECs provides protection from low levels of 
pro-inflammatory cytokines. 
 
A1 expression may modulate immune recruitment 
In addition, A1 has been described as a potential anti-inflammatory molecule 
[10]. Therefore it is feasible that constitutive expression of this molecule, in the 
murine endothelium, protects against both cell death and pro-inflammatory 
cytokine mediated activation by inhibiting/reducing expression of key 
inflammatory adhesion molecules required to recruit lymphocytes. In rat 
allografts, ICAM-1 and VCAM-1 expression are significantly increased on 
capillary endothelia, whilst only VCAM-1 expression was observed on arteries 
and arterioles, during acute transplantation rejection [24]. As expression of both 
ICAM-1 and VCAM-1 on ECs are increased by pro-inflammatory cytokines such 
as TNF-α [30-33], we treated ECs, isolated from the hearts of ICAM-2/A1 
transgenic or non-transgenic littermates, with TNF-α (10ngs/ml) and the 
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expression of the aforementioned molecules were assessed via flow cytometry. 
ECs isolated from both non-transgenic littermates and ICAM-2/A1 mice 
expressed ICAM-1 and VCAM-1 at low levels (data not shown). As expected 
TNF-α induced expression of ICAM-1 and VCAM-1 on ECs isolated from non-
transgenic mice by a 2 to 5-fold increase (Figure 3B). However, although not 
significant, reduced ICAM-1 and VCAM-1 expression was observed when A1 
was expressed in ECs, in all three experiments (Figure 3B). Next, to analyse 
whether this reduction in adhesion molecules expression lead to an altered cell 
infiltration, cardiac grafts were harvested from mice receiving an ICAM-2/A1 
heart or a non-transgenic heart, day 100 post transplantation, and tissue 
sections were stained with H&E. At this time point ICAM-2/A1 heart but not non-
transgenic heart where still palpitating. An intact heart structure, with little 
leukocyte infiltration, was observed in the A1 expressing heart and there was no 
evidence of cardiac allograft vasculopathy in coronary vessels. In contrast, 
diffuse myocardial inflammation with extensive myocyte damage, haemorrhage, 
fibrosis and vasculitis was seen in the non-transgenic heart (Figure 3C, 
increased magnification shown in insert box). To rule out that the diminished 
infiltration seen was due to A1 expressing DCs having a reduced capacity to 
activate T cells, antigen specific CD4 and CD8 T cells were stimulated with 
antigen pulsed DCs isolated from ICAM-2/A1 or non-transgenic mice and T cell 
proliferation measured. DCs isolated from ICAM-2/A1 mice stimulated both CD4 
and CD8 T cell responses to the same extent as DCs isolated from control mice 
(data not shown). In conclusion, constitutive expression of A1 may protect 
murine ECs from pro-inflammatory cytokine mediated cell death and activation, 
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both of which may have lead to the prolonged allograft survival observed in 
vivo.  
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 Discussion 
 
During transplantation, EC dysregulation is the key initiator of graft rejection and 
inhibiting EC activation is an effective way to prevent graft loss. Over 
expressing anti-apoptotic genes such as HO and A20 in ECs protects ECs from 
cytokine mediated activation and cell death [2,3]. In addition, anti-apoptotic 
molecules are expressed in ‘accepted’ graft tissues [2]. In this study we extend 
these findings to Bfl-1/A1, a TNFα-inducible anti-apoptotic molecule. In ECs, 
under normal conditions, A1 is either expressed at low levels, or not at all, but it 
is induced via NF-kB activation in responses to inflammatory stimuli. 
Overexpression of this molecule has been shown previously to inhibit ECs 
activation [10] making it a promising anti-inflammatory and cytoprotective 
molecule for these cells.  
 
It has been reported that A1, like other Bcl-2 family members, is located in the 
mitochondria where it binds to Bid and tBid to inhibit the activation of the pro-
apoptotic Bcl-2 family members, Bak and Bax [12] [34]. A1 has four Bcl-2 
homology (BH) domains in addition to a C-terminal domain containing an 
amphipathic tail. Expression of full length A1 by recombinant adenovirus (rAd.) 
has been shown to protect human ECs from staurosporine [35] and TNF-
induced cell death [15]. This maybe due to both the BH4 and C-terminal 
domains of this molecule, both of which have been reported to be involved in 
the anti-apoptotic function of A1 [36]. Here, we show that constitutive 
expression of A1 can protect murine ECs from low levels of TNF-α in vitro. This 
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pro-inflammatory cytokine has been shown to be an important mediator of 
allograft rejection [28]. In a rat cardiac transplant model, TNF-α protein levels 
within allografts were maximal 3 days post transplant [37]. Whether A1 
expression in the murine endothelium protects against this early in vivo 
production of TNF-α is as yet unknown. 
  
A1 has also been shown to inhibit NF-kB activation in ECs [10] suggesting that 
this molecule could have an anti-inflammatory function in ECs. Interestingly 
however, Guedes et al (2013) observed that when human HUVEC and HDMEC 
were transduced with recombinant adenovirus (rAd.) expressing full length 
human A1 (rAd.A1), TNF-induced upregulation of ICAM-1 in ECs was not 
inhibited, reflecting a lack of inhibited of NF-kB activation, as measured by IKBα 
degradation. This result contradicted their earlier research on BAEC where they 
expressed A1 via transfection with an A1 plasmid [18,35]. However, expression 
of full length A1, using rAd.A1, in bovine ECs gave the same result as in human 
cells with respect to IKBα degradation [35]. These authors concluded that full 
length A1 does not inhibit NF-kB activation. However they observed that 
expressing only the C-terminal domain of A1, using rAd., in human ECs led to 
an anti-inflammatory effect, as shown by a lack of ICAM-1 upregulation in 
response to TNF-α [35]. They suggested that cleavage of A1 at the C-terminal 
domain maybe important for its anti-inflammatory effect, possibly by releasing 
A1 from the mitochondria, given that the C-terminus is crucial for anchoring A1 
to this organelle. We found that constitutive expression of full-length murine A1 
in murine vascular ECs appears to reduce, although minimal and not 
 16 
statistically significance, the induction of both ICAM-1 and VCAM-1 following 
TNF-α stimulation. In addition, reduced immune infiltration was observed in 
heart allografts expressing A1 in murine vascular ECs, suggesting perhaps a 
limited expression of adhesion molecules on these cells. Whether the difference 
between our study and that of Guedes et al (2013) reflects a difference in 
species used and type of EC studied (HUVEC and HDMEC versus murine 
vascular ECs) or a level of expression difference (rAd transduction vs 
endogenous ICAM-2 promoter driven expression) is at the moment unknown.  
 
Given that A1 expression increased the mean survival time of transplanted 
murine hearts from 17 to 86 days, assessment of whether expression of Bfl-1 in 
human vascular endothelium also confers protection is warranted. Viral vectors, 
to target molecules to vascular endothelium, are limited by their lack of 
specificity to just ECs. Several promoters have been used to target EC in vivo. 
Lei et al (2007) used adenoviral vectors containing an ICAM-2 promoter, linked 
to lacZ to transduced murine hearts ex vivo [38].  These authors found high lacZ 
expression (22-57%) in ECs of the coronary arteries and veins in 4 of 22 donor 
grafts, 3 days following transduction with 1010 pfu virus [38]. Expression was 
ECs specific as no lacZ expression was observed in cardiomyocytes [38]. Given 
our data, we suggest that targeting anti-apoptotic molecules, such as Bfl-1, 
perhaps through adenovirus infection, to ECs, using the ICAM-2 promoter 
maybe a promising targeting strategy for gene therapy. In conjunction with this, 
other therapies may also be required, as expression of A1 did not protect 
against direct pathway activated CD8+ T cells.  
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Figure Legends 
 
Figure 1. Constitutive expression of A1 in ECs protects from cytokine 
mediated cell death in vitro. 
(A) Map of the 1.6Kb Xho1-Not1 microinjection construct, showing the ICAM-2 
promoter, universal intron (UI), A1 cDNA, and SV40 early polyadenylation 
signal sequence (poly(A)). The location of probe used for Southern blot analysis 
is shown as well as the location of primers used for PCR. Founder transgenic 
mice, two shown, are indicated by an (*), were identified by Southern Blotting 
using a 32P labeled injection fragment as a probe (B, top panel) and by PCR 
using specific primers (B, lower panel). 
 
ECs were isolated from the hearts of the ICAM-2/A1 and non-transgenic (NT) 
littermates and grown in vitro for 7 days before the expression levels of CD105 
were assessed using specific conjugated antibodies and flow cytometry (C, 
upper panels). Histograms representing the expression of CD105 in ECs are 
shown compared to unstained or secondary antibody stained ECs. Expression 
of A1 at the mRNA level was assessed using RT-PCR using two A1 specific 
primers and a control β actin primer (C, lower panels). A1 mRNA is indicated 
using an (*).  
 
Figure 2. Expression of A1 in murine ECs prolongs graft survival. 
CBA mice received hearts from either ICAM-2/A1 or non-transgenic  (NT) 
littermates in the absence (A) or presence (B) of anti-CD8 antibody given 1 day 
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before and after transplantation (250µgs/mouse). Results plotted show the MST 
of allografts and n= number of animals. P values are shown.  
 
Figure 3. Reduced VCAM-1 and ICAM-1 expression in ECs expressing A1 
may reduce leucocyte infiltration  
ECs isolated from ICAM-2/A1 (filled bars) and non-transgenic (open bars) 
littermates were stimulated with increasing concentrations of TNF-α (0.01-
10ngs/ml) in the presence of 1µgs/ml of Act D. Control ECs received Act D only. 
After 24 hours cell survival was measured using an MTT assay. The percent 
survival was measured by comparing TNF-α stimulated ECs to control Act D, 
which were deemed 100% viable. Data represents the pool of 5 experiments 
and the Mean +/SEM is shown (A). Statistical significance is shown using (*). 
 
ECs isolated from ICAM-2/A1 (black bars) and non-transgenic (open bars) 
littermates were stimulated with 10ngs/ml of TNFα for 24 hours. Expression of 
ICAM-1 and VCAM-1 were analysed via flow cytometry using specific 
antibodies and the fold changed of expression comparing to non-stimulated 
ECs is shown. Data represents the pooled mean +/- SEM of 3 experiments, 
lines indicate the comparison between ICAM-2/A1 and non-transgenic mice per 
individual experiment (B). Heart transplants were explanted on day 100 and 
sections taken for H&E staining (C). Insert picture shows leucocyte infiltration 
around a blood vessel highlighted in the black box. 
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